Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Shionogi

A pill can stop people from developing COVID after being exposed to the virus, trial finds

A pill called ensitrelvir is the first drug shown to effectively reduce infection after exposure to SARS-CoV-2.

LiveScience

D-Wave Quantum Q1 Earnings Call Highlights

D-Wave Quantum (NYSE:QBTS) reported a sharp increase in first-quarter bookings and said demand for its quantum computing systems has strengthened, even as revenue declined from a year earlier when results included a major system sale. On the company’s first-quarter 2026 earnings call, Chief Executi

MarketBeat

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks to Buy to Power Through April

The biotech sector is primed for growth, fueled by a surge in FDA approvals, anticipated M&A deals, and the integration of AI in drug discovery. So, fundamentally sound biotech stocks Theratechnologies (THTX), Harmony Biosciences (HRMY), and Shionogi & Co. (SGIOY) might be solid buys in this month. Keep reading.

StockNews.com

The biotech industry’s rapid expansion is driven by rising healthcare sending, groundbreaking innovations, and strategic collaborations, propelling the growth of biopharma companies. Thus, it could be wise to invest in popular biotech stocks Illumina (ILMN), Shionogi (SGIOY), and Regeneron Pharmaceuticals (REGN) for substantial gains. Keep reading….

StockNews.com

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

StockNews.com

Unlocking Biotech's Potential With 3 Stocks to Buy

The biotech industry’s growth is propelled by strong demand for medical support and interventions, favorable government initiatives, and rapid adoption of emerging technologies. Given the industry’s tailwinds, quality biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and Corcept Therapeutics (CORT) could be ideal buys now. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Top Biotech Stocks to Purchase Right Away

The ever-rising demand for quality healthcare is expected to benefit the biotech industry. Moreover, favorable government initiatives to boost domestic biotech research and production should boost the industry’s prospects. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi & Co. (SGIOY), Amicus Therapeutics (FOLD), and Entrada Therapeutics…

StockNews.com

Japan to join international efforts against drug-resistant bacteria

Japan will participate in an international clinical trial to identify treatments against infections caused by drug-resistant bacteria, it has been learned.

The Japan News/Yomiuri

Shionogi says Japan government to buy 1 million more COVID pill doses

Shionogi Co Ltd said on Tuesday the Japanese government agreed to purchase an additional 1 million doses of its oral treatment for COVID-19.

Reuters

COVID pill approval ups pandemic arsenal

The health ministry has granted emergency approval for a COVID-19 pill developed by Shionogi Co., opening the door for Japan's first domestically produced oral medicine for the virus to become available as soon as early December.

The Japan News/Yomiuri

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Insufficient proof behind rejection of Shionogi COVID-19 drug

A COVID-19 pill developed by Shionogi Co. has failed to win fast-track emergency approval because experts sought scientifically convincing data to prove its efficacy, rather than focusing on the need for more treatment options amid the seventh wave of novel coronavirus infections.

The Japan News/Yomiuri

EXPLAINER: COVID-19 pills must be taken within 5 days

COVID-19 patients have two treatment options that can be taken at home

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Reuters

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus

An experimental treatment from Shionogi Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.

Tribune News Service

Pfizer's COVID pill is poised to be among the fastest-selling treatments of all time

Demand for Covid pills is set to make Pfizer Inc.’s Paxlovid among the fastest-selling treatments of all time, with revenue of almost $24 billion expected in 2022, according to a forecast from analytics group Airfinity Ltd.

Benzinga

Japan-Based Shinogi's COVID-19 Drug Associated With Birth Defects: Bloomberg

Shionogi & Co stock slumped 16% in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval. Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution. The animal data, which showed harm when given at high doses, was…

The Japan News/Yomiuri

Shionogi to apply for approval of first Japan-made oral COVID drug

Japanese pharmaceutical company Shionogi Co. plans to apply for government approval to sell its oral COVID-19 drug as early as next week, the company announced Monday.

Get all your
news in one place.

100's of premium titles.
One news app.

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Christian Schmollinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.